As the Wnt/beta-catenin pathway is upregulated, at least in genetic ALS mice (15–18), this might partly explain the poor results reported in trials testing riluzole in ALS (23–26). This evidence concerns the gene CTNNB1 and amyotrophic lateral sclerosis.